Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Baxter International Inc. stock logo
BAX
Baxter International
$30.40
+2.7%
$32.39
$26.25
$41.06
$15.59B0.644.55 million shs3.60 million shs
ResMed Inc. stock logo
RMD
ResMed
$236.11
+10.1%
$221.75
$179.00
$263.05
$34.68B0.751.03 million shs2.26 million shs
Solventum Co. stock logo
SOLV
Solventum
$67.52
+2.5%
$72.87
$47.16
$85.92
$11.68BN/A1.31 million shs750,907 shs
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$210.44
-3.5%
$217.91
$187.43
$394.42
$15.21B1.22718,593 shs2.55 million shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Baxter International Inc. stock logo
BAX
Baxter International
+3.60%+6.39%-11.85%-8.68%-27.76%
ResMed Inc. stock logo
RMD
ResMed
+0.18%+1.42%-3.66%-13.70%+16.65%
Solventum Co. stock logo
SOLV
Solventum
+1.43%+0.38%-11.17%-10.39%+3.86%
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
+1.22%+3.92%-6.23%-36.76%-44.23%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Baxter International Inc. stock logo
BAX
Baxter International
4.693 of 5 stars
3.24.01.74.02.61.72.5
ResMed Inc. stock logo
RMD
ResMed
3.8234 of 5 stars
2.31.03.34.62.11.71.3
Solventum Co. stock logo
SOLV
Solventum
1.602 of 5 stars
3.04.00.00.02.70.00.0
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
4.6273 of 5 stars
3.55.01.73.22.11.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Baxter International Inc. stock logo
BAX
Baxter International
2.40
Hold$38.5626.83% Upside
ResMed Inc. stock logo
RMD
ResMed
2.60
Moderate Buy$254.317.71% Upside
Solventum Co. stock logo
SOLV
Solventum
2.00
Hold$79.8618.27% Upside
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
3.00
Buy$332.5058.00% Upside

Current Analyst Ratings Breakdown

Latest SOLV, RMD, WST, and BAX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$274.00
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$247.00 ➝ $255.00
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$290.00 ➝ $285.00
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$286.00 ➝ $290.00
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$260.00 ➝ $248.00
4/21/2025
ResMed Inc. stock logo
RMD
ResMed
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$280.00 ➝ $269.00
4/21/2025
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/16/2025
ResMed Inc. stock logo
RMD
ResMed
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$265.00
3/19/2025
ResMed Inc. stock logo
RMD
ResMed
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$280.00
3/18/2025
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$275.00
3/10/2025
Baxter International Inc. stock logo
BAX
Baxter International
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$39.00 ➝ $41.00
(Data available from 4/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Baxter International Inc. stock logo
BAX
Baxter International
$10.64B1.47$4.71 per share6.45$16.69 per share1.82
ResMed Inc. stock logo
RMD
ResMed
$4.93B7.04$9.36 per share25.23$35.77 per share6.60
Solventum Co. stock logo
SOLV
Solventum
$8.25B1.42N/AN/AN/A
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$2.89B5.26$9.31 per share22.60$37.10 per share5.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Baxter International Inc. stock logo
BAX
Baxter International
-$649M-$1.28N/A11.140.93-5.05%16.67%4.93%5/1/2025 (Estimated)
ResMed Inc. stock logo
RMD
ResMed
$1.02B$8.4727.8822.791.5325.34%26.17%18.60%N/A
Solventum Co. stock logo
SOLV
Solventum
N/A$2.7524.5512.301.94N/AN/AN/A5/8/2025 (Estimated)
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$492.70M$6.6931.4626.776.7417.03%18.60%13.80%4/24/2025 (Estimated)

Latest SOLV, RMD, WST, and BAX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Solventum Co. stock logo
SOLV
Solventum
$1.19N/AN/AN/A$2.02 billionN/A
5/1/2025Q1 2025
Baxter International Inc. stock logo
BAX
Baxter International
$0.48N/AN/AN/A$2.59 billionN/A
4/24/2025Q1 2025
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$1.30$1.45+$0.15$1.23$685.24 millionN/A
4/23/2025Q3 2025
ResMed Inc. stock logo
RMD
ResMed
$2.37$2.37N/A$2.48$1.28 billion$1.29 billion
2/20/2025Q4 2024
Baxter International Inc. stock logo
BAX
Baxter International
$0.52$0.58+$0.06-$1.00$2.67 billion$2.75 billion
2/13/2025Q4 2024
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$1.75$1.82+$0.07$1.78$739.59 million$748.80 million
1/30/2025Q2 2025
ResMed Inc. stock logo
RMD
ResMed
$2.29$2.43+$0.14$2.34$1.27 billionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Baxter International Inc. stock logo
BAX
Baxter International
$0.682.24%-1.40%N/A N/A
ResMed Inc. stock logo
RMD
ResMed
$2.120.90%+7.63%25.03%13 Years
Solventum Co. stock logo
SOLV
Solventum
N/AN/AN/AN/AN/A
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$0.840.40%-4.48%12.56%N/A

Latest SOLV, RMD, WST, and BAX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2025
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
quarterly$0.210.39%7/30/20258/6/2025
4/24/2025
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.530.9%5/8/20255/8/20256/12/2025
2/20/2025
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
quarterly$0.210.41%4/30/20254/30/20255/7/2025
2/11/2025
Baxter International Inc. stock logo
BAX
Baxter International
quarterly$0.172.22%2/28/20252/28/20254/1/2025
1/30/2025
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.530.9%2/13/20252/13/20253/20/2025
1/28/2025
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
quarterly$0.210.2%2/7/20252/7/20252/11/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Baxter International Inc. stock logo
BAX
Baxter International
1.31
1.43
1.09
ResMed Inc. stock logo
RMD
ResMed
0.13
3.33
2.29
Solventum Co. stock logo
SOLV
Solventum
2.45
1.15
0.83
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
0.08
2.79
2.23

Institutional Ownership

CompanyInstitutional Ownership
Baxter International Inc. stock logo
BAX
Baxter International
90.19%
ResMed Inc. stock logo
RMD
ResMed
54.98%
Solventum Co. stock logo
SOLV
Solventum
N/A
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
93.90%

Insider Ownership

CompanyInsider Ownership
Baxter International Inc. stock logo
BAX
Baxter International
0.21%
ResMed Inc. stock logo
RMD
ResMed
0.71%
Solventum Co. stock logo
SOLV
Solventum
0.05%
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
0.53%
CompanyEmployeesShares OutstandingFree FloatOptionable
Baxter International Inc. stock logo
BAX
Baxter International
60,000512.92 million509.47 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
8,160146.87 million145.82 millionOptionable
Solventum Co. stock logo
SOLV
Solventum
22,000173.00 millionN/AOptionable
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
10,70072.29 million71.92 millionOptionable

Recent News About These Companies

West Announces Leadership Changes
Validea Detailed Fundamental Analysis - WST

New MarketBeat Followers Over Time

Media Sentiment Over Time

Baxter International stock logo

Baxter International NYSE:BAX

$30.40 +0.80 (+2.70%)
As of 03:59 PM Eastern

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

ResMed stock logo

ResMed NYSE:RMD

$236.11 +21.67 (+10.11%)
As of 03:59 PM Eastern

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Solventum stock logo

Solventum NYSE:SOLV

$67.52 +1.62 (+2.46%)
As of 03:59 PM Eastern

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.

West Pharmaceutical Services stock logo

West Pharmaceutical Services NYSE:WST

$210.44 -7.74 (-3.55%)
As of 03:59 PM Eastern

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.